Luye Pharma Gains Approval for Innovative Antidepressant Trials
Express News | Luye Pharma - Approval Obtained for Class 1 Innovative Antidepressant Ly03021 for Clinical Trials in China
Luye Pharma Adjusts Closing Date for Bond Issue
Investors Five-year Losses Continue as Luye Pharma Group (HKG:2186) Dips a Further 4.4% This Week, Earnings Continue to Decline
Luye Pharma Group to Issue $150 Million Convertible Bonds in Two Tranches
Express News | Luye Pharma - Proposed Issue of US$100.0 Mln 5.85 per Cent. Convertible Bonds Due 2025 and US$50.0 Mln 5.85 per Cent. Convertible Bonds Due 2025
Institutions Profited After Luye Pharma Group Ltd.'s (HKG:2186) Market Cap Rose HK$451m Last Week but Private Companies Profited the Most
Citi Upgrades Luye Pharma to Buy From Sell; Price Target Is HK$4
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Luye Pharma Group Reports Strong Mid-Year Financials
Express News | Luye Pharma Group H1 Revenue RMB 3,074.6 Million
Express News | Luye Pharma Group H1 Gross Profit RMB 2,078.6 Million
Express News | Luye Pharma Group H1 Net Income RMB 438.2 Million
Express News | Luye Pharma Group H1 Gross Margin 67.6%
Luye Pharma Sets Date for Financial Results Review
Luye Pharma Group's Subsidiary's Investor Buys 25% Stake in Nanjing Luye for 1 Billion Yuan
Luye Pharma Group Completes Key Investment Phase
China Approves Luye Pharma's Anti-Psychotic Drug for Trials; Shares Jump 5%
Luye Pharma's Breakthrough Drug Enters Clinical Trials
Express News | Luye Pharma -Approval Obtained for Initiating Clinical Trials for- Innovative Dual Taar1/5-Ht2Cr Agonist
No Data
No Data